Quarterly report pursuant to Section 13 or 15(d)

Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)

v3.5.0.2
Note 1 - Nature of Operations and Summary of Significant Accounting Policies (Tables)
 9 Months Ended
Sep. 30, 2016
Notes Tables  
Schedule of Franchisor Disclosure [Table Text Block]
    Three Months Ended
 September 30,		   Nine Months Ended
 September 30,
Franchised clinics:   2016   2015   2016   2015
Clinics in operation at beginning of period     280       239       265       242  
Opened during the period     13       13       38       36  
Acquired during the period     -       (2 )     (6 )     (23 )
Closed during the period     -       (2 )     (4 )     (7 )
Clinics in operation at the end of the period     293       248       293       248  
    Three Months Ended
 September 30,		   Nine Months Ended
 September 30,
Company-owned or managed clinics:   2016   2015   2016   2015
Clinics in operation at beginning of period     61       23       47       4  
Opened during the period     -       4       8       4  
Acquired during the period     -       2       6       23  
Closed during the period     -       -       -       (2 )
Clinics in operation at the end of the period     61       29       61       29  
                                 
Total clinics in operation at the end of the period     354       277       354       277  
                                 
Clinics licenses sold but not yet developed     134       180       134       180  
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]
    Three Months Ended
September 30,		   Nine Months Ended
September 30,
    2016   2015   2016   2015
                 
Net loss   $ (2,626,894 )   $ (1,656,722 )   $ (9,413,407 )   $ (5,416,317 )
                                 
Weighted average common shares outstanding - basic     12,730,624       9,844,964       12,657,435       9,777,119  
Effect of dilutive securities:                                
Stock options     -       -       -       -  
Weighted average common shares outstanding - diluted     12,730,624       9,844,964       12,657,435       9,777,119  
                                 
Basic and diluted loss per share   $ (0.21 )   $ (0.17 )   $ (0.74 )   $ (0.55 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]
    Three Months Ended
September 30,		   Nine Months Ended
September 30,
    2016   2015   2016   2015
Unvested restricted stock     92,415       116,818       92,415       453,846  
Stock options     899,370       271,895       899,370       376,275  
Warrants     90,000       90,000       90,000       90,000